OpGen Valuation Multiples

Discover OpGen's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like ToolGen, Atrys Health, Veraxa Biotech, Korro Bio and more.

OpGen Overview

About OpGen

OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.


Founded

2001

HQ

United States

Employees

4

Website

opgen.com

Financials (FY)

Revenue: -
Net Income: -

EV

$245M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

OpGen Stock Performance

OpGen has current market cap of $244M, and enterprise value of $245M.

EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$245M$244M-----

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

OpGen Valuation Multiples

OpGen Financial Valuation Multiples

As of August 23, 2026, OpGen has market cap of $244M and EV of $245M.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified OpGen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

OpGen Competitors

OpGen competitors include ToolGen, Atrys Health, Veraxa Biotech, Korro Bio, Myriad Genetics, Prenetics Global, Tauns Laboratories, Cibus, Anixa Biosciences and electroCore.

Most OpGen public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
ToolGen259.0x-(9.6x)-
Atrys Health3.1x2.4x(41.4x)14.6x
Veraxa Biotech9443.0x-(3.4x)-
Korro Bio19.0x49.0x(1.1x)(1.3x)
Myriad Genetics0.5x0.5x(1.2x)(17.9x)
Prenetics Global2.5x1.3x(6.9x)(8.9x)
Tauns Laboratories3.9x4.8x8.0x13.5x
Cibus39.1x30.6x(1.6x)(2.3x)

This data is available for Pro users. Sign up to see all OpGen competitors and their valuation data.

Start Free Trial

Acquisitions by OpGen

OpGen has acquired 1 company to date.

Last acquisition by OpGen was on July 14th 2015. OpGen acquired AdvanDx for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by OpGen

AdvanDx
Description
AdvanDx is a Woburn, Massachusetts-headquartered provider of molecular diagnostics for infectious diseases in hospitals. The company offers FDA-cleared assays like SeptiFast for sepsis pathogens and EasyMAG for nucleic acid extraction. Founded in 2002, it serves over 500 laboratories in Europe and North America with automated PCR workflows.
HQ CountryUnited States
HQ City
Boston, MA
Deal Date14 Jul 2015
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all OpGen acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About OpGen

When was OpGen founded?OpGen was founded in 2001.
Where is OpGen headquartered?OpGen is headquartered in United States.
How many employees does OpGen have?As of today, OpGen has over 4 employees.
Is OpGen publicly listed?Yes, OpGen is a public company listed on Berlin Stock Exchange.
What is the stock symbol of OpGen?OpGen trades under 650 ticker.
When did OpGen go public?OpGen went public in 2015.
Who are competitors of OpGen?OpGen main competitors include ToolGen, Atrys Health, Veraxa Biotech, Korro Bio, Myriad Genetics, Prenetics Global, Tauns Laboratories, Cibus, Anixa Biosciences, electroCore.
What is the current market cap of OpGen?OpGen's current market cap is $244M.
Is OpGen profitable?No, OpGen is not profitable.
How many companies OpGen has acquired to date?As of August 2026, OpGen has acquired 1 company.
What was the largest acquisition by OpGen?None of the M&A deals OpGen has completed have disclosed valuations.
What companies OpGen acquired?OpGen acquired AdvanDx.
In how many companies OpGen has invested to date?OpGen hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to OpGen

Lists including OpGen

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial